Fingerprint
Dive into the research topics of 'The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics
David C. Wheeler, Bergur V. Stefansson, Mikhail Batiushin, Oleksandr Bilchenko, David Z.I. Cherney, Glenn M. Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits-Filho, Hans Furuland, José Luis Górriz, Tom Greene, Hermann Haller, Fan Fan Hou, Shin Wook Kang, Rey Isidto, Dinesh Khullar, Patrick B. Mark, John J.V. McMurray
Research output: Contribution to journal › Article › peer-review
112
Scopus
citations